메뉴 건너뛰기




Volumn 12, Issue 1, 2013, Pages 12-14

Real-life outcomes of Maraviroc-based regimens in HIV-1-infected individuals

Author keywords

Efficacy; HIV; Maraviroc; Tolerability

Indexed keywords

DARUNAVIR; MARAVIROC; RIFAMPICIN; RITONAVIR; VIRUS RNA;

EID: 84877877278     PISSN: 23259574     EISSN: 23259582     Source Type: Journal    
DOI: 10.1177/1545109712462454     Document Type: Article
Times cited : (5)

References (12)
  • 1
    • 27644510382 scopus 로고    scopus 로고
    • Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity
    • Dorr P, Westby M, Dobbs S, et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother. 2005;49(11):4721-4732.
    • (2005) Antimicrob Agents Chemother. , vol.49 , Issue.11 , pp. 4721-4732
    • Dorr, P.1    Westby, M.2    Dobbs, S.3
  • 3
    • 84859947440 scopus 로고    scopus 로고
    • Consensus statement of the European guidelines on clinical management of HIV-1 tropism testing
    • O121
    • Vandekerckhove LPR, Wensing AMJ, Kaiser R, et al. O121. Consensus statement of the European guidelines on clinical management of HIV-1 tropism testing. J Int AIDS Soc. 2010; 13(suppl 4):O7.
    • (2010) J Int AIDS Soc. , vol.13 , Issue.SUPPL. 4
    • Vandekerckhove, L.P.R.1    Wensing, A.M.J.2    Kaiser, R.3
  • 4
  • 5
    • 84877915338 scopus 로고    scopus 로고
    • accessed April 25, 2011
    • Food and Drugs Administration. 2011 Full prescribing information: Celsentri. http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/ 022128s004lbl.pdf. Accessed April 25, 2011.
    • 2011 Full Prescribing Information: Celsentri
  • 6
    • 80052476919 scopus 로고    scopus 로고
    • Optimization of clinically relevant cut-points for the determination of HIV co-receptor usage to predict maraviroc responses in treatment experienced (TE) patients using population V3 genotyping [abstract PE3.4/8]
    • Cologne, Germany
    • McGovern RA, Dong W, Mo T, et al. In: Program and abstracts of the 12th European AIDS Conference. Optimization of clinically relevant cut-points for the determination of HIV co-receptor usage to predict Maraviroc responses in treatment experienced (TE) patients using population V3 genotyping [abstract PE3.4/8]. Cologne, Germany; 2009:11-14.
    • (2009) Program and Abstracts of the 12th European AIDS Conference , pp. 11-14
    • McGovern, R.A.1    Dong, W.2    Mo, T.3
  • 7
    • 33846932573 scopus 로고    scopus 로고
    • HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: Aids clinical trial group A5211
    • Wilkin TJ, Su Z, Kuritzkes DR, et al. HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. Clin Infect Dis. 2007;44(4): 591-595.
    • (2007) Clin Infect Dis. , vol.44 , Issue.4 , pp. 591-595
    • Wilkin, T.J.1    Su, Z.2    Kuritzkes, D.R.3
  • 8
    • 54849146700 scopus 로고    scopus 로고
    • Maraviroc for previously treated patients with R5 HIV-1 infection
    • Gulick RM, Lalezari J, Goodrich J, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med. 2008; 359(14):1429-1441.
    • (2008) N Engl J Med. , vol.359 , Issue.14 , pp. 1429-1441
    • Gulick, R.M.1    Lalezari, J.2    Goodrich, J.3
  • 9
    • 35048870707 scopus 로고    scopus 로고
    • Efficacy and safety of maraviroc in antiretroviral-experienced patients infected with CCR5-tropic HIV-1: 48 week results of MOTIVATE 1
    • Paper presented at Chicago, IL
    • Lalezari J, Goodrich J, DeJesus E, et al. Efficacy and safety of Maraviroc in antiretroviral-experienced patients infected with CCR5-tropic HIV-1: 48 week results of MOTIVATE 1. Paper presented at 47th International Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL; 2007.
    • (2007) 47th International Conference on Antimicrobial Agents and Chemotherapy
    • Lalezari, J.1    Goodrich, J.2    DeJesus, E.3
  • 10
    • 55049103539 scopus 로고    scopus 로고
    • Efficacy and safety of maraviroc plus optimized background therapy in viraemic, antiretroviral treatment-experienced patients infected with CCR5-tropic HIV-1 in Europe, Australia, and North America (MOTIVATE2): 48 week results
    • Paper presented at Madrid, Spain
    • Fatkenheuer G, Konaourina I, Nelson M, et al. Efficacy and safety of Maraviroc plus optimized background therapy in viraemic, antiretroviral treatment-experienced patients infected with CCR5-tropic HIV-1 in Europe, Australia, and North America (MOTIVATE2): 48 week results. Paper presented at 11th European AIDS Conference. Madrid, Spain; 2007.
    • (2007) 11th European AIDS Conference
    • Fatkenheuer, G.1    Konaourina, I.2    Nelson, M.3
  • 12
    • 77749271329 scopus 로고    scopus 로고
    • Maraviroc versus efavirenz, both in combination with zidovudine- lamivudine, for the treatment of antiretroviral-naïve subjects with CCR5-tropic HIV-1 infection
    • Cooper DA, Heera J, Goodrich J, et al. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naïve subjects with CCR5-tropic HIV-1 infection. J Infect Dis. 2010;201(6):803-813.
    • (2010) J Infect Dis. , vol.201 , Issue.6 , pp. 803-813
    • Cooper, D.A.1    Heera, J.2    Goodrich, J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.